Suppression of adjuvant-induced arthritis by liposomally conjugated methotrexate in the rat.
A phospholipid conjugate of methotrexate was synthesized and liposomally formulated in order to determine whether such a formulation could modulate the severity of experimentally induced arthritis in the rat. Lewis rats were immunized with Mycobacterium butyricum and after the onset of joint inflammation were treated intravenously with methotrexate liposomes (MTX-LIPO). This preparation was significantly better in reducing established joint inflammation than comparable doses of the free drug or empty liposomes of identical lipid composition. Haematopoietic toxicity associated with MTX-LIPO was significantly less than seen with comparable doses of the free drug.
Williams
A S
AS
Rheumatology Research Laboratory, University of Wales College of Medicine, Heath Park, Cardiff.
Camilleri
J P
JP
Williams
B D
BD
D000818:Animals; D001170:Arthritis, Infectious / Q000188:drug therapy*; D004195:Disease Models, Animal; D004337:Drug Carriers; D008081:Liposomes; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D009161:Mycobacterium; D010714:Phosphatidylethanolamines; D051381:Rats; D011917:Rats, Inbred Lew; D012720:Severity of Illness Index
D004337:Drug Carriers; D008081:Liposomes; D010714:Phosphatidylethanolamines; D008727:Methotrexate; C018525:1,2-dimyristoylphosphatidylethanolamine